Agios Pharmaceuticals
Healthcare & Life Sci
Company overview
Agios Pharmaceuticals is a biopharmaceutical company developing therapies for rare hemolytic and acquired anemias, including pyruvate kinase deficiency, thalassemia and sickle cell disease. Its drug mitapivat became the first disease-modifying therapy for pyruvate kinase deficiency, approved by the FDA in April 2022. Agios is headquartered in Cambridge, Massachusetts.
The company was founded in 2007-2008 by Lewis Cantley, Tak Mak and Craig Thompson, and went public on NASDAQ under ticker AGIO in July 2013. It employed 536 people as of 2025, a small enough team that individual scientists working on these rare-disease programs can see their work reach patients directly.
Currently, there are no job openings at Agios Pharmaceuticals. Over the last 30 days, 0 jobs were added and 0 were removed. Agios Pharmaceuticals is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cambridge, United States